Search - tctmd.com

Displaying 1 - 20 of 24

Sort: Relevancy | Date

Presentation ACC 2025

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Presenter: Darren K. McGuire

March 29, 2025

Presentation ACC 2024

Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy

Presenter: Eric Quinton Klug

April 07, 2024

Presentation ACC 2024

Comparison of an “Inclisiran First” Strategy With Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial

Presenter: Michael J. Koren

April 06, 2024

Presentation Controversies and Advances 2023

Obesity and Cardiovascular Disease

Presenter: Steven E. Nissen

November 30, 2023

Presentation TCT 2023

TCT 249: Remnant Cholesterol as a Residual Risk in Patients with Atherosclerotic Cardiovascular Disease under Moderate-intensity Statin with Ezetimibe Combination Therapy or High-intensity Statin Monotherapy

Presenter: Jung-Hee Lee

October 25, 2023

Presentation ACC 2023

A Randomized Trial Assessing The Impact Of Eliminating Copayment For High Value Preventive Medications For Low-income Seniors With Cardiovascular-related Chronic Diseases

Presenter: Braden Manns

March 06, 2023

Presentation ACC 2023

A Cluster Randomized Trial of a Personalized Clinical Decision Support Intervention to Improve Statin Prescribing in Patients With Atherosclerotic Cardiovascular Disease (PCDS Statin)

Presenter: Salim Virani

March 05, 2023

Presentation ACC 2023

A Cluster-Randomized Trial to Improve Care of Patients in Cardiology Clinics with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease [COORDINATE-Diabetes]

Presenter: Neha J. Pagidipati

March 05, 2023

Presentation ESC 2022

Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease: Primary Results of the FOURIER-OLE (Open-Label Extension) Studies

Presenter: Michelle L. O’Donoghue

August 29, 2022

Presentation ACC 2020

The Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes and Cardiovascular Disease: COMPASS Diabetes

Presenter: Deepal L. Bhatt

March 30, 2020

Presentation AHA 2018

Safety and Efficacy of AKCEA-APO(a)-LRx to Lower Lipoprotein(a) Levels in Patients With Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial

Presenter: Sotirios Tsimikas

November 11, 2018

Presentation ESC 2018

Association of dietary quality and risk of cardiovascular disease and mortality in 218,000 people from over 50 countries

Presenter: Andrew Mente

August 30, 2018

Presentation The Structural Heart Disease Summit 2018

Intraprocedural Efficiencies

Presenter: Janet F. Wyman

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Patient Selection: Making the Subjective Objective (Frailty, Depression)

Presenter: Marian C. Hawkey

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Diagnostic Evaluation: Historical Requirements and Emerging Evidence (LHC, TTE, TEE, CTA, Carotid US, PFTs)

Presenter: Kim Guibone

June 21, 2018

Presentation EAS 2018

Stress, Behavior and Cardiovascular Disease

Presenter: Viola Vaccarino

May 06, 2018

Presentation ACC 2018

Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout and Cardiovascular Disease (The CARES Trial)

Presenter: William B. White

March 11, 2018

Presentation

Chronic Ischaemic Cardiovascular Disease (CICD) ESC Pilot Registry: 6-Month Follow-Up

January 19, 2018

Presentation AHA 2017

Time at Blood Pressure Target and the Risk of Cardiovascular Diseases and Mortality

Presenter: Mar Pujades-Rodriguez

November 14, 2017

Presentation TCT 2017

Valvular Heart Disease: Diagnosis and Treatment Options 2017

Presenter: Grzegorz L. Kaluza, Jose M. Wiley, Nicola Corvaja

October 29, 2017

Advertisement

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy

Comparison of an “Inclisiran First” Strategy With Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial

Obesity and Cardiovascular Disease

TCT 249: Remnant Cholesterol as a Residual Risk in Patients with Atherosclerotic Cardiovascular Disease under Moderate-intensity Statin with Ezetimibe Combination Therapy or High-intensity Statin Monotherapy

A Randomized Trial Assessing The Impact Of Eliminating Copayment For High Value Preventive Medications For Low-income Seniors With Cardiovascular-related Chronic Diseases

A Cluster Randomized Trial of a Personalized Clinical Decision Support Intervention to Improve Statin Prescribing in Patients With Atherosclerotic Cardiovascular Disease (PCDS Statin)

A Cluster-Randomized Trial to Improve Care of Patients in Cardiology Clinics with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease [COORDINATE-Diabetes]

Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease: Primary Results of the FOURIER-OLE (Open-Label Extension) Studies

The Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes and Cardiovascular Disease: COMPASS Diabetes

Safety and Efficacy of AKCEA-APO(a)-LRx to Lower Lipoprotein(a) Levels in Patients With Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial

Association of dietary quality and risk of cardiovascular disease and mortality in 218,000 people from over 50 countries

Intraprocedural Efficiencies

Patient Selection: Making the Subjective Objective (Frailty, Depression)

Diagnostic Evaluation: Historical Requirements and Emerging Evidence (LHC, TTE, TEE, CTA, Carotid US, PFTs)

Stress, Behavior and Cardiovascular Disease

Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout and Cardiovascular Disease (The CARES Trial)

Chronic Ischaemic Cardiovascular Disease (CICD) ESC Pilot Registry: 6-Month Follow-Up

Time at Blood Pressure Target and the Risk of Cardiovascular Diseases and Mortality

Valvular Heart Disease: Diagnosis and Treatment Options 2017

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content